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Introduction
Systemic administration of pharmaceuticals is frequently used
in modern medicine.[1] In the last decade, supramolecular ag-
gregates such as micelles and vesicles have attracted great at-
tention for their potential application as carriers in drug deliv-
ery. Their base requirements in systemic administration include
high drug-loading capacity, biodegradability, prolonged circula-
tion times, slow plasma clearance, and controllable drug-re-
lease profiles.[2, 3] The hydrophobic core of micelles and the
inner cavity of vesicles are carrier compartments that can ac-
commodate large amounts of drug, whereas the shell, consist-
ing of a brush-like protecting corona, stabilizes them in aque-
ous solutions. To increase therapeutic or diagnostic efficacy of
the administered drug and reduce potential toxic side effects
on non-target organs, the development of schemes aimed at
achieving more specific and selective delivery to target cells
constitutes a major challenge for many clinical applications. In
particular, applications of such schemes would be of great in-
terest for the management of patients affected by cancer.
The targeting capabilities of peptides and antibodies raised
against a specific molecular target have been proposed to ach-
ieve such selective delivery.[4, 5] Antibodies show very high se-
lectivity for their antigens but present some drawbacks such as
a slow extravasation process due to their high molecular
weight.[6] Moreover, high-molecular-weight molecules, such as
immunoglobulins (150 kDa), have very slow capillary permea-
bility which prevent them from reaching the target molecules
with ideal timing.
The use of peptides as targeting tools has been validated in
a number of applications.[7, 8] One example are radiolabeled
peptides which are used in nuclear medicine techniques to
perform imaging or to deliver radiotherapeutic doses to cancer
tissues, overexpressing particular types of receptors such as
those for somatostatin.[9] In this case, a simple entity such as
the radionuclide is driven by the peptide to target cells at
higher concentrations compared to non-target organs. A more
New nanocarriers are obtained by assembling two amphiphilic
monomers: one containing the bioactive peptide CCK8 spaced,
by a polydisperse poly(ethylene glycol), from two hydrophobic
tails ((C18)2PEG2000CCK8), and the other containing a chelating
agent able to give stable radiolabeled indium-111 complexes
linked to the same hydrophobic moiety ((C18)2DTPAGlu). The size
and shape of the supramolecular aggregates were structurally
characterized by dynamic light scattering, small-angle neutron
scattering, and cryogenic transmission electronic microscopy.
Under the experimental conditions we investigated (pH 7.4 and
molar ratio between monomers 30:70), there is the presence of
high polydisperse aggregates : rod-like micelles with a radius of
~40 1 and length >700 1, open bilayer fragments with thickness
~65 1, and probably vesicles. The presence of the bioactive pep-
tide well exposed on the external surface of the aggregate allows
selective targeting of nanocarriers towards the cholecystokinin re-
ceptors overexpressed by the cancerous cells. In vitro binding
assays and in vivo biodistribution studies by nuclear medicine ex-
periments using indium-111 are reported. Moreover, preliminary
data concerning the drug loading capability of the aggregates
and their drug efficiency on the target cells is reported by using
the cytotoxic drug doxorubicin. Incubation of receptor-positive
and control cells with peptide-containing aggregates filled with
doxorubicin shows significantly lower cell survival in receptor-ex-
pressing cells relative to the control, for samples incubated in the
presence of doxorubicin.
[a] Dr. G. Mangiapia, Dr. M. Vaccaro, Prof. L. Paduano
Department of Chemistry, University of Naples “Federico II”
Via Cynthia, 80126 Napoli (Italy)
Fax: (+39)081-674-090
[b] Dr. A. Accardo, Dr. D. Tesauro, Prof. C. Pedone, Prof. G. Morelli
CIRPeB, Department of Biological Sciences & IBB CNR
University of Naples “Federico II”
Via Mezzocannone 16, 80134 Napoli (Italy)
Fax: (+39)081-253-6642
E-mail : gmorelli@unina.it
[c] Dr. L. Aloj, Dr. L. Tarallo
Department of Nuclear Medicine
Istituto Nazionale per lo Studio e la Cura dei Tumouri
Fondazione “G. Pascale”
Via M. Semmola, 80131 Napoli (Italy)
[d] Dr. C. Arra
Department of Animal Experimentation
Istituto Nazionale per lo Studio e la Cura dei Tumouri
Fondazione “G. Pascale”
Via M. Semmola, 80131 Napoli (Italy)
Supporting information for this article is available on the WWW under
http://www.chemmedchem.org or from the author.
594 www.chemmedchem.org < 2008 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemMedChem 2008, 3, 594 – 602
MED
complex and challenging objective would be to adopt a similar
scheme to deliver supramolecular aggregates, such as micelles
or vesicles, to a tissue of interest. Such aggregates, as men-
tioned above, could be used as nanovectors for large quanti-
ties of drugs contained in the inner cavity of the supramolec-
ular aggregate. Examples of target specific supramolecular ag-
gregates, employed as vectors of drugs or metal complexes,
include micelles and vesicles loaded with poorly soluble anti-
cancer agents[4,10] or bearing GdIII complexes.[11,12] In these
cases the aggregates are externally modified with tumor spe-
cific antibodies.
An effective way to prepare supramolecular aggregates
modified on the surface with a reporter compound is the
mixed assembling of different monomers. With this strategy,
we have recently developed mixed aggregate systems, acting
as high relaxivity MRI contrast agents,[13–15] formed by two dif-
ferent amphiphilic monomers, one containing a bioactive pep-
tide and the other a chelating moiety capable of forming
stable complexes with Gd ACHTUNGTRENNUNG(III) ions.
We have now developed new mixed aggregates with en-
hanced properties and studied them as potential target selec-
tive nanovectors of drugs. The new nanovectors are obtained
by mixing the monomers reported in Figure 1. The lipophilic
moiety of both monomers, consisting of two C18 alkyl chains,
allows the formation of the aggregates, whereas the CCK8
peptide and the anionic DTPAGlu chelating agent remain
mainly exposed on the nanovector external surface. CCK8 is
the C-terminal sequence of the cholecystokinin hormone and
provides the binding sequence for the cholecystokinin recep-
tor subtypes 1 and 2 (CCK1-R and CCK2-R): its binding affinity
toward the two receptors is in the nanomolar range.[16] Overex-
pression of both of these receptor subtypes has been demon-
strated in certain human tumors.[17] To obtain adequate dis-
tancing of the bioactive peptide from the surface of the supra-
molecular aggregate, and reduce potential hindrance to its
specific binding activity, a hydrophilic spacer is introduced be-
tween the N terminus of the peptide and the lipophilic tails.
Poly(ethylene glycol) (PEG2000 MW=2000) was chosen because
of its size and the well-known empathy for water. The pres-
ence of long chains exposed on the surface of the aggregates,
such as those obtained using high-molecular-weight PEG as
spacer, prevents them from being cleared through the reticu-
lo-endothelial system (RES).[18] Furthermore it also avoids ad-
sorption of blood proteins onto the supramolecular surface
and, thus, the protective capacity of the PEG corona is of pri-
mary importance for the in vivo use of the supramolecular ag-
gregates.[19] The bifunctional chelating agent, a DTPA deriva-
tive, is bound on the lipophilic moiety of the other monomer.
It was chosen for its ability to give stable complexes with dif-
ferent metals such as the radioactive metals used for diagnos-
tic or therapeutic nuclear medicine applications, thus allowing
the in vivo visualization of the nanovectors.[20] The ability of
the new aggregates to act as target selective nanovectors is
demonstrated in vitro and in vivo; moreover a preliminary
study concerning the drug loading capability and the drug ac-
tivity on target cells, using the well-known cytotoxic drug Dox-
orubicin, is reported.
Results and Discussion
The knowledge of the structural parameters (shape and size)
of the aggregates is a crucial step in the development of nano-
carriers for drug delivery. The aggregate dimension and their
nature (spherical or rod-like micelles, vesicles, or liposomes)
could determine the in vivo stability and biodistribution of the
nanocarriers, and the rate of drug release.[21] Moreover the se-
lective binding of the peptide containing nanocarriers to the
target receptor site is only possible if the bioactive peptide se-
quence is well-exposed on the aggregate’s external surface,
thus enhancing the probability for an effective homing of
nanovectors on the selected target.
We have already reported that the structure obtained by
self-assembling anionic surfactants such as (C18)2DTPAGlu can
be influenced by several parameters such as pH, temperature,
ionic strength of the medium, and chemical composition of
the solvent.[22] Moreover, when a second nonionic monomer is
introduced in the aggregate a structural transition can occur.
In the mixed aggregates the molar ratio between the two
monomers plays a crucial role in the assembly process.[15] In
this study we fixed pH at physiological levels (pH 7.4),
and the molar ratio between the monomers
((C18)2DTPAGlu/ ACHTUNGTRENNUNG(C18)2PEG2000CCK8) at 70:30). To characterize
the supramolecular aggregates obtained by mixing the two
synthetic monomers, a fully structural characterization was car-
ried out by using several physicochemical techniques.
Figure 1. Schematic representation of the two monomers ((C18)2PEG2000CCK8 and (C18)2DTPAGlu) employed to formulate mixed aggregates.
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Structural characterization
Structural characterization has been performed on the supra-
molecular aggregates that appear very stable: they present
very low cmc values: 1.8G106m for the self-assembled
(C18)2PEG2000CCK8 and 2.1G10
6m for the mixed aggregate
(C18)2DTPAGlu/ ACHTUNGTRENNUNG(C18)2PEG2000CCK8.
Microstructural parameters of the aggregates present in so-
lution as well as the presence of possible a coexisting popula-
tion of aggregates differing in size and shape have been ob-
tained by light and neutron scattering techniques (DLS and
SANS) and cryogenic transmission electron microscopy (Cryo-
TEM). The DLS relaxation time distributions are monomodal at
all angles studied, with a very broad peak that suggests the
co-presence in solution of a wide spread of aggregates, see
Figure 2a. The linear relation of the relaxation rate as a func-
tion of q2 confirms that the mode is due to translational diffu-
sion processes, attributed to a complex with apparent transla-
tional diffusion coefficient D= (1.660.01)G1012 m2s. This
data can be directly related to the hydrodynamic radius of the
aggregate, RH, through the Stokes-Einstein equation:
RH ¼
kBT
6phD
ð1Þ
where kB is the Boltzmann constant, T is the absolute tem-
perature, and h is the medium viscosity. The value obtained for
the hydrodynamic radius was of about 12010 I.
The above results were confirmed by the SANS measure-
ments. In fact the scattering cross section dS/dW, reported in
Figure 2b shows a q2 decay at low q values, which is typical
of bilayer scattering (open bilayers and/or closed vesicles) and
a q1 decay in the intermediate q range as expected in the
presence of rod-like micelles.[23]
In all cases, the supramolecular aggregates appear to con-
tain both monomers as suggested by a considerable increase
in scattering cross section observed in samples obtained with
the addition of the (C18)2PEG2000CCK8 monomer with respect
to the already reported self-assembling obtained by
(C18)2DTPAGlu amphiphile.
[22] The observed increase reflects
the additional contribution to the scattering cross section, due
to the presence of (C18)2PEG2000CCK8 in these aggregates.
[24]
The structural parameters of the aggregates have been ob-
tained using the models as reported in the experimental sec-
tion, and are summarized in Table 1.
The analysis of the bilayer structure (thickness ~65 I, length
~800–1000 I) and the length of poly(ethylene glycol) spacer
suggest that the bioactive peptide is completely exposed on
the external surface of the ag-
gregates and available for re-
ceptor binding. In fact according
to the crystallographic data, the
length of the PEG2000, present in
the shell, should be around
30 I,[25] that is, quite larger than
the polar heads exposed by
(C18)2DTPAGlu monomers on
Figure 2. a) Relaxation time distributions at q 458–1208 for (C18)2DTPAGlu-
(C18)2PEG2000-CCK8 (70:30) aqueous solution at pH 7.4. b) Experimental
small-angle neutron scattering data collected on (C18)2DTPAGlu-
(C18)2PEG2000CCK8 (70:30 molar ratio) mixed aggregates. Fitting of the data
according to the respective model gives the solid lines shown for the two
samples.
Table 1. Summary of structural parameters obtained by SANS and DLS techniques.
System R [I][a] l [I][a] d [I][b] D [1012m2s1][c] RH [I]
[c]
ACHTUNGTRENNUNG(C18)2DTPAGlu-(C18)2PEG2000CCK8-water 373 70020 659 1.660.01 12020
[a] R and l are radius and length of rod-like micelles. [b] d is the thickness of double bilayers. [c] D and RH are
diffusion coefficient and hydrodynamic radius of the aggregates as measured by DLS.
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the hydrophilic shell (~20 I). The same arguments hold in the
case of rod-like micelles whose radius is ~40 I and length is
above 700 I. The total number of monomers in
(C18)2DTPAGlu/ ACHTUNGTRENNUNG(C18)2PEG2000CCK8 mixed aggregates is expect-
ed to be above 200 for the rod-like micelles and ~2G105 for
bilayers. In all aggregates there is a large water penetration,
due to the steric repulsion among the charged DTPAGlu
heads.
The cryo-TEM image reported in Figure 3 shows the pres-
ence of hollow tubes that can correspond to open bilayers
structures, whereas vesicles have not been detected.
Thus, in the experimental conditions we investigated, there
is the presence of polydisperse kinds of aggregates, such as
rod-like micelles, bilayer fragments, and probably vesicles, in
solution as the broad peak obtained by DLS suggests. In the
already reported (C18)2DTPAGlu self-assembling system
[22] the
relaxation time distribution at physiological pH revealed the
contemporary presence of micelles and bilayer structures or
vesicles and that the dominant aggregates present in the
system were micelles. The micelle formation is explained by
the high negative charge of the surfactant head group, which
causes strong head group–head group interactions. In the
mixed system, described herein, the (C18)2PEG2000CCK8 nonion-
ic monomer interposes among (C18)2DTPAGlu units, partially
shielding the electrostatic repulsions between the chelating
agent polar heads and promoting the formation of bilayers.
In vitro biological assays
As already reported for other mixed aggregate systems,[15] re-
ceptor binding ability can be evaluated by standard nuclear
medicine experiments. Radiolabeling of the aggregates was
performed at concentrations above critical micellar concentra-
tion to avoid the presence of free monomers in solution. Trace
amounts of 111InCl3 and up to 500 mCi were added to the ag-
gregate formulation after addition of an equal volume of 0.5 n
Sodium Citrate. Confirmation of incorporation of the label into
the aggregates was obtained by gel filtration. 111In-labeled ag-
gregates showed preferential binding to A431 cells overex-
pressing the CCK2-R by transfection (Figure 4a) compared to
control cells. As a certain degree of nonspecific binding and in-
ternalization of the aggregates was expected, experiments
were performed both at 4 8C (to block cellular metabolic pro-
cesses such as nonspecific internalization) and at 37 8C (to
keep metabolic processes active). Specific targeting on recep-
tor expressing cells was demonstrated as these cells showed
significantly higher retention of label compared to control
cells. Although these differences were fairly small they were
confirmed by performing competition experiments with excess
unlabeled free CCK8 peptide that displaced all specifically
bound aggregate to background levels. No significant differen-
ces in accumulation on receptor positive cells was observed
between cells incubated at 37 8C and 4 8C for the incubation
time (1 h) tested, indicating little, if any, internalization during
the short observation period of the experiment. Although
uptake levels overall were fairly low, receptor targeting both at
37 and 4 8C allowed a several-fold increase in cell associated
activity on A431-CCK2-R cells compared to controls.
In vivo binding and biodistribution studies
111In-labeled aggregates were also used to determine in vivo
properties of the nanovectors and their ability to target in vivo
receptor positive tumor with respect to control tumor. Results
of the biodistribution experiments at 18 h are shown in Fig-
ure 4b. Overall retention of the radiolabel in the experimental
animals was very high, with essentially no excretion of the
starting radioactivity over the observation period. Biodistribu-
tion of the labeled aggregates is consistent with a fairly low
plasma clearance. All organs showed high retention of radioac-
tivity although this was particularly evident in organs with
high blood pool such as liver and spleen. There was higher
concentration of the aggregates in the receptor expressing
xenografts. Direct comparisons of tumor uptake within the
same animal showed statistically significant enrichment of the
aggregates in the receptor expressing xenografts (Paired t-test,
P=0.01) compared to control. The average enrichment factor
was found to be 4821% (mean SD, percent increase of
weight normalized radioactivity in receptor positive versus ra-
dioactivity in receptor negative tumors, corrected for radioac-
tivity present in blood and interstitial space of the tumor).[26]
To maintain the aggregates stable, high concentration of the
monomers was used to stay above the critical micellar concen-
tration. Surfactants (2 mg in 100 mL of solution) were injected
in each animal. Although milligram quantities of aggregates
were injected, we did not observe any significant side effect
following the i.v. administration of the compound and during
the 18 h observation period.
Figure 3. Cryo-TEM image of mixed aggregates formed by (C18)2DTPAGlu
and (C18)2PEG2000CCK8. Circular spots are artifacts.
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Figure 4c shows the gamma camera image of a mouse from
the biodistribution experiment taken prior to dissection. The
image clearly shows increased accumulation of the radiola-
beled aggregates in the receptor positive xenograft compared
to surrounding tissues and the contralateral control tumor.
Very high retention was also observed in liver and spleen, two
high blood pool organs. The receptor positive tumor clearly
stands out compared to the background activity that is fairly
uniform and high in the remaining organs, in agreement with
the data obtained from the cut-up experiments. All the inject-
ed radioactivity is recovered from the animals after 18 h. This
indicates that the aggregates have fairly long circulating half-
life and very little clearance through digestive or urinary tract.
The elevated concentrations in high blood pool organs and
the considerable ability to concentrate in the receptor express-
ing xenografts are all in line with desired and necessary phar-
macokinetic properties of a drug delivery nanovector.
Doxorubicin loading and in vitro assays
Doxorubicin was loaded in the hydrophobic core of the rod-
like micelles and open bilayers by hydrating the lipid film for
30 min with a solution of doxorubicin buffered at pH 7.4. The
phosphate buffer was diluted at 0.01m (instead 0.1m used for
the physicochemical characterization) because of the poor sol-
ubility of doxorubicin in phosphate solution over the range of
pH 5.0–8.5.[27] The doxorubicin loading content was calculated
by fluorescence measurements for subtraction of the amount
of free doxorubicin, eluted by gel filtration, from the total
amount of loaded doxorubicin.[28] The high value of doxorubi-
cin loading content (DLC higher than 99% of the total) allows
the use of the doxorubicin containing aggregates as obtained.
The amount of doxorubicin molecules per aggregate (2:1) was
calculated taking into account the aggregation number (about
200 monomers per micelle). These amounts do not represent
the doxorubicin loading efficiency of the aggregates or the
upper limit of loading, but the ratio chosen for the experi-
ments. Cytotoxicity studies were carried out by a cell growth
inhibition assay. Cells were treated for 16 h with aggregates
containing doxorubicin at different final doxorubicin concen-
trations, ranging between 20 and 200 ngmL1, and then incu-
bated for another four days after which cell survival was as-
sessed using a sulforhodamine B assay.[29] Control experiments
performed with increasing concentrations of the empty aggre-
gates showed no significant killing effect in both cell systems
at concentrations of monomer up to 500 ngmL1. Data were
Figure 4. Biological characterization of radiolabeled nanovectors. a) Binding
of 111In-labeled aggregates to A431 cells overexpressing the CCK2-R by trans-
fection compared to control cells. Binding is measured at two different tem-
peratures, 4 and 37 8C. b) Biodistribution results of experiments performed
in receptor positive and receptor negative xenografts bearing nude mice
18 h after injection. Organs with high blood pool such as liver and spleen
displayed highest activity retention levels. c) Gamma camera image (dorsal
view) obtained prior to dissection of one of the animals 18 h after injection
of radiolabeled aggregates clearly shows higher concentration of the radio-
label in the receptor positive xenograft (+, left flank) compared to the con-
trol tumor (, right flank). These differences were statistically significant
when comparing data from the five animals (paired t-test, P=0.01).
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plotted as the percentage of surviving cells compared to the
control cells. Incubation of receptor-positive and control cells
(Figure 5) showed significantly lower cell survival in receptor-
expressing cells for samples incubated in the presence of the
higher amounts of doxorubicin (final concentrations of 100
and 200 ngmL1). Lower concentrations of the drug containing
aggregates (not shown) showed a lower overall killing effect
and no significant differences between receptor positive and
receptor negative cells.
These preliminary findings indicate that specific interaction
of the peptide-containing aggregates with their receptor
indeed increases the therapeutic efficacy of the doxorubicin
containing aggregates. At lower concentrations receptor spe-
cific killing is not observed likely due to lower receptor occu-
pancy secondary to dilution of the aggregates. In preliminary
experiments performed with doxorubicin alone under the
same conditions higher cell killing was observed for the same
concentrations and no differences between the receptor ex-
pressing and nonexpressing cell lines (data not shown), sug-
gesting that when doxorubicin is loaded into the aggregates
its toxicity is significantly reduced probably because the drug
is not as readily available to enter the cells as when placed di-
rectly in the culture medium.
Conclusions
In conclusion, under the experimental conditions we investi-
gated, the monomers described herein form a variety of aggre-
gates of different shapes and sizes: rod-like micelles with a
radius of ~40 I and length above 700 I, bilayer fragments
with thickness ~65 I, and probably vesicles. Notwithstanding
the high polydisperse kind aggregates, biological tests show
properties that appear potentially suitable for clinical applica-
tions: 1) significantly higher concentration of aggregates in re-
ceptor expressing xenografts relative to controls has been es-
tablished in vivo, suggesting that these aggregates may be
used to increase concentration of a therapeutic or diagnostic
agent to tissues expressing a specific receptor target; 2) slow
plasma kinetics with prolonged half-life and low breakdown of
the supramolecular aggregates, both probably due to the pres-
ence of PEG2000 moieties on the aggregate external surface,
[18,19]
appear useful for maintaining high blood concentrations of
the desired agent.
The ability of surface exposed peptides to target nanovec-
tors to a specific organ/tissue gives promising new opportuni-
ties for the development of pharmaceutical agents with higher
selectivity toward a biological target and may potentially
reduce toxic side effects on nontarget organs. In particular
these aggregates, the use of which we are evaluating, appear
to increase delivery of doxorubicin to receptor-positive cells as
confirmed by the increased killing effect obtained in these
cells compared to nonreceptor expressing controls.
Experimental Section
Materials and methods
Protected Na-Fmoc amino acid derivatives, coupling reagents, and
Rink amide MBHA resin were purchased from Calbiochem-Novabio-
chem (Laufelfingen, Switzerland). Fmoc-NH-PEG2000-NHS (MW=
2384 Da) was purchased from Nektar therapeutics (Huntsville, AL).
All other chemicals were commercially available by Sigma–Aldrich
or Fluka (Bucks, Switzerland) or LabScan (Stillorgan, Dublin, Ireland)
and were used as received unless otherwise stated. N,N-dioctade-
cylsuccinamic acid was synthesized according to the literature.[30]
All solutions were prepared by weight with doubly distilled water.
Samples to be measured by Small Angle Neutron Scattering
(SANS) techniques were prepared using heavy water (Sigma–Al-
drich, purity> 99.8%). The pH of all solutions was kept constant at
7.4. Doxorubicin HCl, (commercial name of (8S,10S)-10-(4-amino-5-
hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-
(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydro-tetracene-5,12-
dione) was purchased from Sigma–Aldrich.
Preparation of (C18H37)2NCOACHTUNGTRENNUNG(CH2)2COLys ACHTUNGTRENNUNG(DTPAGlu)CONH2
((C18)2DTPAGlu)
The synthesis of (C18H37)2NCO ACHTUNGTRENNUNG(CH2)2COLys ACHTUNGTRENNUNG(DTPAGlu)CONH2 mono-
mer was carried out as previously described.[22]
Preparation of (C18H37)2-NCOACHTUNGTRENNUNG(CH2)2CO-PEG2000-G-CCK8
((C18)2PEG2000CCK8)
Synthesis of the (C18H37)2-NCOACHTUNGTRENNUNG(CH2)2CO-PEG2000-G-CCK8 monomer
was carried out in solid-phase using a 433A Applied Biosystems au-
tomatic synthesizer under standard conditions and Fmoc strat-
egy.[31] Rink-amide MBHA resin (0.78 mmolg1, 1.0 mmol scale,
1.28 g) was used. The peptide chain was elongated by sequential
coupling and Fmoc deprotection of the following Fmoc-amino
acid derivative: Fmoc-Phe-OH, Fmoc-Asp ACHTUNGTRENNUNG(OtBu)-OH, Fmoc-Met-OH,
Fmoc-Trp ACHTUNGTRENNUNG(Boc)-OH, Fmoc-Gly-OH, Fmoc-Met-OH, Fmoc-Tyr ACHTUNGTRENNUNG(tBu)-OH,
Fmoc-Asp ACHTUNGTRENNUNG(OtBu)-OH, Fmoc-Gly-OH. All couplings were performed
twice for 1 h, by using an excess of four equivalents for the single
amino acid derivative. The a-amino acids were activated in situ by
the standard conditions by using hydroxybenzotriazole/benzotria-
Figure 5. Cell survival assays of CCK2-R overexpressing and control A431
cells incubated with different amounts of doxorubicin containing vesicles for
16 h then followed for four further days. A receptor specific effect is ob-
served in cells incubated with high concentrations of doxorubicin. No recep-
tor specificity was observed at the lower concentrations although some cell
killing effect was evident in both cell lines.
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zol-1-yloxytris(pyrrolidino) phosphonium/N,N-diisopropylethyla-
mine (HOBt/PyBop/DIPEA) procedure. N,N-dimethylformamide
(DMF) was used as a solvent. Fmoc deprotection was carried out
by 20% solution of piperidine in DMF after the coupling of each
amino acid residue. The coupling steps were monitored by the
qualitative Kaiser test. When the peptidic synthesis was complete,
the Fmoc N-terminal protecting group was removed and Fmoc-
NH-PEG2000-NHS residue condensed. The coupling was performed
in DMF twice for 1 h, by using an excess of 1.5 equivalents and
3.0 equiv of DIPEA. The coupling reaction was monitored by the
qualitative Kaiser test. Fmoc deprotection was carrier out by 20%
solution of piperidine in DMF. Than, N,N-dioctadecylsuccinamic
acid was bonded on the a-NH2 of PEG2000 hydroxy spacer. The cou-
pling was carried out by an excess of four equivalents (0.622 g,
1 mmol) of the lipophilic compound dissolved in 3 mL of N,N-di-
methylformamide/dichloromethane/N-methylpyrrolidone DMF/
DCM/NMP (1:1:1) mixture. PyBop (0.520 g, 1.0 mmol), HOBt
(0.153 g, 1.0 mmol), and DIPEA (335 mL, 2.0 mmol), dissolved in
DMF were introduced in the vessel like activating agents. The cou-
pling time was 1 h under N2 flow at room temperature. The mono-
mer-resin was treated with an acidic solution of trifluoroacetic
acid/triisopropylsilane/water TFA/TIS/H2O (95.5:2.0:2.5) mixture.
The crude product was precipitated at 0 8C by adding water drop-
wise. Purification of the crude mixture was carried out by RP-HPLC
using a Waters model Delta Prep 4000 chromatograph. Product
was analyzed for purity by Shimadzu 10A-LC HPLC equipped with
a Phenomenex C18 column and for identity by ESI-MS using a Finni-
gan Surveyor MSQ single quadrupole electrospray ionization mass
spectrometer (Finnigan/Thermo Electron Corporation San Jose).
Analytical RP-HPLC indicated a purity >95%. ACHTUNGTRENNUNG(C18)2PEG2000CCK8,
Rt=27.1 min; MW=3774 amu; [M+3H
+]/3=1259.0 amu
Sample preparation
All solutions were prepared by weight, buffering the samples at
pH 7.4 by using 0,1m phosphate buffer. pH was controlled by
using pH-meter MeterLab PHM 220. In most cases the samples to
be measured were prepared from stock solutions. Aggregates
were prepared by dissolving the amphiphiles, in the molar ratio
(C18)2DTPAGlu/ ACHTUNGTRENNUNG(C18)2PEG2000CCK8) 70:30, in a small amount of a
methanol/chloroform (50:50) mixture, and subsequently evaporat-
ing the solvent by slowly rotating the tube containing the solution
under a stream of nitrogen. In this way a slowly formed thin film
of amphiphile was obtained. After leaving the film under reduced
pressure for several hours, the organic solvent was evaporated.
Then the film was hydrated by addition of 0.1m phosphate buffer
(pH 7.4) solution in the vial and stirred for 1 h by vortex. The prod-
uct was successively subjected to sonication for 1 h, and finally ex-
truded pushing the solution ten times through a polycarbonate
membrane with 100 nm pore size. Extrusion procedure was per-
formed by using the Avanti Mini extruder available by Avanti Polar
Lipids (USA and Canada).
Small-angle neutron scattering (SANS)
Small-angle neutron scattering measurements performed at Neu-
tron facilities Berlin Neutron Scattering Centre, Hahn-Meitner-Insti-
tute, Berlin, Germany. Neutrons with an average wavelength l of
7 I and a wavelength spread Dl/l<0.1 were used. The configura-
tions adopted allowed collection of the scattering cross section in
an interval of transferred moment q ranging, depending on the fa-
cilities, between 0.001 and 0.12 I1. The measurement time ranged
between 30 min and 2 h per sample. The raw data, obtained by
studied samples were then corrected for electronic background
and empty cell scattering. Detector efficiency corrections and
transformation to absolute scattering cross sections were made
with appropriate standards, according to standard procedures. Mi-
crostructural parameters of the aggregates have been obtained ap-
plying the appropriate models to the experimental SANS data.
Provided the analyzed solutions are quite dilute, consequent struc-
ture function S(q) can be approximated to the unity, and the scat-
tering cross section dS/dW of a collection of monodisperse bodies
can be described by the following equation[32]
dS
dW
¼ NbPðqÞ þ
dS
dW
 
inch
ð2Þ
where Nb is the number density of scattering bodies, P(q) is the
form factor containing information on the shape of the scattering
objects, and (dS/dW)inch is the incoherent contribution to the total
scattering cross section, mainly due to the presence of hydrogen
nuclei in the sample, that can be evaluated. Micelles and vesicles
resulting from the aggregation processes may assume different
shapes like rods, platelets, spheres, and so on. Scattering from a cy-
lindrical or rod-like structure is characterized by a linear portion in
a Porod (double log) plot of dS/dW vs. q with a slope of 1. Using
the Guinier approximation,[33] cross section for such aggregates can
be written as
dS
dW
¼ ð1 Þ pRD1ð Þ
2
q
exp  q
2R2
4
 
ð3Þ
where Y is the volume fraction of the cylinders, R their radius, DP
representing the contrast between the cylinders and the solvent
(D2O). By plotting ln ACHTUNGTRENNUNG(q dS/dW) versus q from the linear portion is
possible to extract the radius R of cylinders. A lower limit for cylin-
ders length can be obtained analyzing the Guinier region of the
scattering cross section since for d>2p/q the pattern presents a
flattening typical of this region. Scattering from planar structures is
characterized by a linear portion in a Porod plot of dS/dW vs. q
with a slope of 2. In the q range analyzed vesicles can be “ap-
proximated” as bilayer, so the factor structure used is that one for
a planar sheet,[34] given by
dS
dW
¼ 2p D1ð Þ2St2 1
q2
sin2 qt2
 
qt
2
 2 ð4Þ
where t is the bilayer’s thickness and S is the plain surface per
volume.
Dynamic light scattering (DLS)
The setup for the dynamic light scattering measurement was an
ALV/DLS/SLS-5000F, CGF-8F based compact goniometer system
from ALV-GmbH., Langen, Germany. The light source was constitut-
ed by a CW diode-pumped Nd: YAG solid-state Compass-DPSS
laser with a symmetrizer from COHERENT, Inc. , (Santa Clara, Califor-
nia). It operated at 532 nm with a fixed output power of 400 mW.
The laser intensity could be modulated by an external compensat-
ed attenuator from Newport Inc. , USA. A more detailed description
of the instrumentation can be found in the literature with the dif-
ference that decalin was used instead of toluene as a refractive
index matching liquid.[35] The DLS data were analyzed by nonlinear
regression procedures. The models used in the fitting procedures
are expressed with respect to the normalized time correlation func-
tion of the electric field, g(1) (t), whereas the fitting was performed
directly to the experimentally measured time correlation function
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of the scattered intensity G(2)(t) often presented as the normalized
function, g(2)(t)1,[36] and described by the Siegert relation[37,38]
gð2ÞðtÞ  1 ¼ b gð2ÞðtÞ 2 ð5Þ
where b ( 1) is a no ideality factor, which accounts for deviation
from ideal correlation and depends on the experimental geometry.
g(1) (t) can either be a single-exponential or multiexponential decay
with corresponding relaxation times, t, depending on the system
investigated. It can be written as the Laplace transform of the dis-
tribution of relaxation time, A(t):
gð2ÞðtÞ ¼
Zþ1
1
tAðtÞ exp  t
t
 
d ln t ð6Þ
where t=G1, whereas G is the relaxation rate that is used to cal-
culate the diffusion coefficient D. The relaxation time distribution
tA(t) is obtained by regularized inverse Laplace transformation
(RILT) of the measured intensity correlation function using calcula-
tion algorithms REPES, as incorporated in the GENDIST analysis
package.[38–40] The relaxation rate G is obtained from the first
moment of the relaxation time distribution, and from its value the
apparent translational diffusion coefficient D is estimated, by this
relation
D ¼ lim
q!0
G
q2
ð7Þ
Where q is the absolute value of the scattering vector (q=4p n0sin-
ACHTUNGTRENNUNG(q/2)/l), where n0 is the refractive index of the solvent, l is the inci-
dent wavelength, and q is the scattering angle. Thus D is obtained
from the slope of G as a function of q2, where G is measured at dif-
ferent scattering angles (q) ranging from 458 to 1208. The corre-
sponding relaxation time distributions [tA(t) versus logACHTUNGTRENNUNG(t/ms)] , ob-
tained by regularized inverse Laplace transformation of the correla-
tion functions, are presented in Figure 2a.
Cryogenic transmission electronic microscopy (Cryo-TEM)
Cryo-TEM images were carried out at the Chemical Centre of Lund,
Sweden on a Philips 120 Biotwin microscope operating at 120 kV.
A small drop of the sample solution was applied on a copper EM
grid with a holey carbon film, and excess solution was blotted with
a filter paper, leaving thus a thin sample film spanning the holes in
the carbon film. The film was subsequently vitrified at the desired
temperature by quick freezing in liquid ethane and analyzed in the
microscope at about 170 8C. Sample preparation was carried out
in a controlled environment verification system to avoid water
evaporation and to ensure cryofixation of the specimen at a con-
trolled temperature (25 8C).[41]
Biological assays
Radiolabeling of the aggregates was performed at concentrations
of the monomers above 8.0·103m. Trace amounts of 111InCl3 and
up to 500 mCi were added to the aggregate formulation after addi-
tion of an equal volume of 0.5n Sodium Citrate. Confirmation of
incorporation of the label into the aggregates was obtained by gel
filtration on Sephadex G-50 prepacked columns (Pharmacia Bio-
tech). Binding activity was tested on A431 cells overexpressing the
CCK2-R by stable transfection
[29] and compared to control cells.
Assays were performed at 4 and 37 8C on cell suspensions that
were incubated with the radiolabel aggregates for 1 h in the pres-
ence (100-fold excess with respect to CCK8 Kd) or absence of
excess CCK8 peptide. Concentration of the monomers in the cell
binding assays were always kept above 104m. Radioactivity
bound to cells was separated from unbound activity by centrifuga-
tion through dibutyl phthalate in 1.5 mL tubes which were subse-
quently frozen on dry ice, the cell pellet containing portion of the
tube excised and counted in a Wallac gamma counter. Unbound
radioactivity was placed in a separate vial and counted as well. Ex-
periments were performed in triplicate and the percentage of
bound radioactivity determined under the different experimental
conditions.
In vivo experiments
Animal experiments were carried out on six week old female CD1
nude mice (Charles River Italia) in whom subcutaneous xenografts
of A431-CCK2-R overexpressing and control A431 cells were grown
in opposite flanks as previously described.[29] Procedures involving
animals and their care were in conformity with institutional guide-
lines that comply with national and international laws and policies.
Biodistribution and imaging experiments were performed two
weeks after implanting cells (tumor sizes were between 0.5 and
1 g). Approximately 100 mCi of 111In-labeled aggregate preparation
were injected into the lateral tail vein of each mouse (n=5). Imag-
ing was performed at different times after injection, following ad-
ministration of an intraperitoneal anesthetic on a clinical gamma
camera equipped with a medium energy collimator. Eighteen
hours after injection the mice were killed, imaged, and subse-
quently dissected to quantitatively determine organ concentrations
of radioactivity by weighing and counting each dissected organ.
The results were expressed as percentage of the injected doseg-1
normalized to a 20 g mouse. Direct comparisons were also per-
formed in each mouse between the receptor positive and receptor
negative xenografts.
Loading of doxorubicin into aggregates
A mixture of (C18)2DTPAGlu, 8 mg, and of (C18)2PEG2000CCK8,
12 mg, (molar ratio 70:30) was dissolved in 2 mL of MeOH/CHCl3
(50:50). After stirring, the organic solvents were removed under a
slow nitrogen flow and a lipid film was obtained. The lipid film was
hydrated for 30 min by using 10.0 mL of a Doxorubicin solution
(concentration 10 mgmL1) in 0.01m phosphate buffer at pH 7.4.
Doxorubicin concentration, in all experiments, was determined by
spectroscopic measurements (UV or fluorescence) using calibration
curves obtained by measuring absorbance at 480 nm or fluores-
cence emission at 590 nm for several solutions containing different
amounts of free doxorubicin in 0.01m phosphate buffer (pH 7.4).
UV spectra were obtained on a UV-vis Jasco (Easton, MD) Model
440 spectrophotometer with a path length of 1 cm; fluorescence
spectra were recorded on a Jasco Model FP-750 spectrofluorimeter
by using 1.0 cm path length quartz cell. Emission spectra were re-
corded at room temperature. Equal excitation and emission band-
widths were used throughout experiments, with a recording speed
of 125 nmmin1 and automatic selection of the time constant.
Free Doxorubicin was removed by using a Sephadex G50 column
pre-equilibrated with 0.1m phosphate buffer at pH 7.4. All fractions
(150 mL) were collected in eppendorf and analyzed by fluorescence
spectroscopy to determine the amount of free Doxorubicin. The
Doxorubicin-loading content (DLC, defined as the weight percent-
age of Doxorubicin in the aggregates) was quantified for subtrac-
tion of the amount of Doxorubicin removed from the column from
the total amount of Doxorubicin loaded.
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Cell survival assays
The A431 cells overexpressing the CCK2 receptor and control cells
described above were used to assess biological properties of the
drug containing aggregates. Cells were seeded at a density of
1000 cells per well in 96-well plates. The following day a suspen-
sion of the Doxorubicin containing aggregates was added to tripli-
cate wells of control and CCK2-R expressing cells. The overall
volume of medium in each well was kept constant, and the final
concentration of doxorubicin on the cells ranged from 20 to
200 ngmL1. Control experiments, on both cell lines, were per-
formed using increasing amounts of empty aggregates ranging
from 10 to 500 ngmL1. Cells were maintained for approximately
16 h in the presence of the aggregates after which the solution
was removed and fresh medium was added to each well. Cells
were then incubated for an additional four days to assess cell sur-
vival which was performed using the well-established colorimetric
sulforhodamine B assay.[42] Data were plotted as the percentage of
surviving cells compared to untreated cells.
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